Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, multicenter Phase III clinical study of 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the treatment of diabetic macular edema

Next Previous
Trial Profile

A randomized, multicenter Phase III clinical study of 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the treatment of diabetic macular edema

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Sponsors Ocumension Therapeutics

Most Recent Events

  • 13 Jun 2022 New trial record
  • 08 Jun 2022 According to a Alimera Sciences media release, the Ocumension Therapeutics received an IND approval from the National Medical Products Administration for the Phase III clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval to treat diabetic macular edema in mainland China.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top